Literature DB >> 2309815

Labetalol pharmacokinetics in pregnancy-induced hypertension.

R C Rogers1, B M Sibai, W D Whybrew.   

Abstract

Pharmacokinetic parameters of oral labetalol were studied in eight women with pregnancy-induced hypertension in the third trimester of pregnancy. Labetalol exhibited rapid absorption; peak serum concentrations of 881 +/- 219 ng/ml occurred at 20 minutes after labetalol ingestion. The terminal elimination half-life (mean, 1.7 +/- 0.27 hours) was found to be shorter than that reported for normotensive volunteers or nonpregnant hypertensive patients (mean, 6 to 8 hours). A mean apparent oral elimination clearance of 21.8 ml/min/kg compared favorably with that seen in other pregnant and nonpregnant populations. Food delayed the time to peak serum concentration to approximately 60 minutes. Labetalol was detected in fetal cord samples and amniotic fluid samples at concentrations approximately 50% and 16% that of simultaneous maternal vein samples, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2309815     DOI: 10.1016/0002-9378(90)90386-l

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

1.  Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol.

Authors:  E B Erdtsieck-Ernste; M G Feenstra; M H Botterblom; J De Barrios; G J Boer
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 2.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  Regulation of hepatic phase II metabolism in pregnant mice.

Authors:  Xia Wen; Ajay C Donepudi; Paul E Thomas; Angela L Slitt; Roberta S King; Lauren M Aleksunes
Journal:  J Pharmacol Exp Ther       Date:  2012-10-10       Impact factor: 4.030

Review 4.  Pharmacological management of hypertension in pregnancy.

Authors:  Thomas R Easterling
Journal:  Semin Perinatol       Date:  2014-10-11       Impact factor: 3.300

5.  Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients.

Authors:  Teresa Maria J P Carvalho; Ricardo de Carvalho Cavalli; Sérgio P Cunha; Cláudia O de Baraldi; Maria P Marques; Natalícia J Antunes; Ana Leonor P C Godoy; Vera Lucia Lanchote
Journal:  Eur J Clin Pharmacol       Date:  2010-09-17       Impact factor: 2.953

6.  Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.

Authors:  James H Fischer; Gloria E Sarto; Jennifer Hardman; Loraine Endres; Thomas M Jenkins; Sarah J Kilpatrick; Hyunyoung Jeong; Stacie Geller; Kelly Deyo; Patricia A Fischer; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

Review 7.  Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.

Authors:  Gail D Anderson; Darcy B Carr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Hypertension in pregnancy.

Authors:  A Anyaegbunam; C Edwards
Journal:  J Natl Med Assoc       Date:  1994-04       Impact factor: 1.798

Review 9.  Drugs in pregnancy: Pharmacologic and physiologic changes that affect clinical care.

Authors:  Emily A Pinheiro; Catherine S Stika
Journal:  Semin Perinatol       Date:  2020-01-25       Impact factor: 3.300

Review 10.  Is personalized medicine achievable in obstetrics?

Authors:  Sara K Quinney; Avinash S Patil; David A Flockhart
Journal:  Semin Perinatol       Date:  2014-10-03       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.